Q-omics provides the consensus-scored CBLN4 profile across patient tissues and cancer cell-line models. CBLN4 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, CBLN4 is differentially expressed in 12, with the highest sampling consensus in KIRC. Additionally, CBLN4 RNA expression shows 14,149 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight UVM, and KIRC as cancer lineages where CBLN4 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CBLN4 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CBLN4 survival associations across molecular data types. CBLN4 RNA expression shows survival associations in the most cancer types (23), followed by mutation status (7) and mass-spec protein abundance (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CBLN4 RNA expression–survival associations across cancer types. High CBLN4 expression shows unfavorable associations in UVM, STAD and KIRP, but favorable associations in ACC, LUAD and CESC. The UVM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UVM as the clearest survival context for CBLN4 RNA expression.
This table summarizes CBLN4 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for CBLN4. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CBLN4 shows lower tumor expression in UCEC, LUAD, LUSC and READ and higher tumor expression in KIRC and THCA. The KIRC box plot shows higher CBLN4 RNA expression in tumor versus normal tissue (log2 FC = +1.207, t-test p < 0.001).
This table shows molecular features associated with CBLN4 in patient tissues and cancer cell lines. In patient samples, CBLN4 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, CBLN4 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_NSCLC_LUAD, while CRISPR and shRNA rows add functional-dependency signals in CNS and BLOOD_Leukemia.
